<DOC>
	<DOCNO>NCT01958047</DOCNO>
	<brief_summary>This study investigate ASP3652 take , broken , distribute body excreted individual different race . The study also investigate level biochemical marker bloodstream , determine safe study drug well tolerate dose . A aim look process metabolism , distribution excretion study drug possibly alter daily diet volunteer take part .</brief_summary>
	<brief_title>A Study Assess Effect Race How Single Dose ASP3652 Taken , Metabolized Distributed Through Bodies Young , Healthy Male Female Subjects , Its Safety Tolerability</brief_title>
	<detailed_description>This open label study ass pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , safety tolerability single dose ASP3652 healthy male female subject Caucasian , Japanese , Black/African Chinese origin . A total 64 healthy male female subject include study ( 16 subject per race group ) . Each race group comprise 8 female subject 8 male subject . Screening assessment perform Day -22 Day -2 , subject admitted clinic Day -1 , remain Day 4 . On Day 1 , subject receive single oral dose ASP3652 , discharge Day 4 assessment perform medical reason stay longer . An end study visit ( ESV ) perform 7-14 day discharge . For race group , plasma sample PK PD analysis collect . Vital sign , safety electrocardiogram ( ECG ) measurement , safety laboratory assessment , physical examination , adverse event ( AEs ) concomitant medication monitor throughout study . In order identify potential relationship dietary intake PK single dose ASP3652 , subject record diet 3 day screen period order assess daily dietary intake ( include total daily caloric intake ; daily cholesterol intake ; total fat , saturate fat , carbohydrate protein percentage total calorie ) .</detailed_description>
	<criteria>The subject healthy male female subject Caucasian , Japanese , Black/African Chinese origin . Both parent 4 grandparent race . Subjects Japanese Chinese origin bear respective country live outside country 5 year 10 year , respectively . The subject Body Mass Index ( BMI ) range 18.5 30.0 kg/m2 , inclusive ( subject Caucasian Black/African origin ) range 17.5 29.0 kg/m2 , inclusive ( subject Japanese Chinese origin ) . The subject weigh least 50 kg ( subject Caucasian Black/African origin ) least 45 kg ( subject Japanese Chinese origin ) . Female subject pregnant , pregnant within 6 month screen , breast feeding within 3 month screen . Known suspected hypersensitivity ASP3652 component formulation use . The subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior admission Clinical Unit .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Phase I</keyword>
	<keyword>ASP3652</keyword>
	<keyword>Single dose</keyword>
	<keyword>Dietary intake</keyword>
</DOC>